StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Several other brokerages also recently commented on PRQR. Chardan Capital upgraded shares of ProQR Therapeutics from a neutral rating to a buy rating and set a $2.00 target price […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among […]
StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a hold rating to a buy rating in a research note issued to investors on Monday. A number of other brokerages have also issued reports on PRQR. Chardan Capital reaffirmed a neutral rating and issued a $2.00 price target on shares of ProQR Therapeutics […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.48 and traded as low as $1.16. ProQR Therapeutics shares last traded at $1.23, with a volume of 330,034 shares. Wall Street Analyst Weigh In […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among […]